1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structureactivity relationships as inhibitors of the human and murine soluble epoxide hydrolase (sEH). Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors. For example, 1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (52) showed a 7-fold increase in potency, a 65-fold increase in C max , and a 3300-fold increase in AUC over its adamantane analogue 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl)urea (2). This novel sEH inhibitor showed a 1000-fold increase in potency when compared to morphine by reducing hyperalgesia as measured by mechanical withdrawal threshold using the in vivo carrageenan induced inflammatory pain model.
Introduction
The soluble epoxide hydrolase (sEH, a EC 3.3.2.3) converts epoxides to the corresponding diols by the catalytic addition of a water molecule. The enzyme is implicated in several disease states for its ability to metabolize fatty acid epoxides such as epoxyeicosatrienoic acids (EETs) and leukotoxin, important endogenous signaling lipids, to less active dihydroxyeicosatrienoic acids (DHETs) 1 and toxic, proinflammatory leukotoxin diols, 2 respectively. sEH inhibitors are of growing interest for therapeutic use because they have been shown to increase the in vivo concentration of EETs and other fatty acid epoxides, resulting in anti-inflammatory, 3 antihypertensive, 4 neuroprotective, 5 and cardioprotective effects. [6] [7] [8] Several reviews have been published concerning the mechanism of action and diverse biological roles of EETs and the sEH inhibitors that stabilize them. [9] [10] [11] [12] [13] [14] [15] [16] Of particular note, Marino 17 recently reviewed the chemistry of sEH inhibitors and Shen 18 summarized the patent literature in the sEH field. The prototypical inhibitors dicyclohexylurea and 12-(3-adamantane-1-ylureido)dodecanoic acid (AUDA), while potent in vitro, suffer from poor physical properties and poor in vivo stability. Amides, carbamates, and other pharmacophores 17, 18 have been explored as alternative pharmacophores in an attempt to improve physical properties and show structure-activity relationships similar to those of ureas, but the disubstituted ureas remain the most studied class of inhibitors because of their high potency [19] [20] [21] [22] [23] and promising pharmacokinetics. 24, 25 Although earlier studies found that trisubstituted ureas had reduced potency, 9, 26 with proper substituents piperidine based trisubstituted ureas have been found to be potent inhibitors of the enzyme. [27] [28] [29] [30] In the past year several other promising pharmacophores have been reported. 17, 18, 21, 28, 31 We previously reported inhibitors incorporating a polar moiety, such as an N-acylpiperidine or cyclohexyloxybenzoic acid, to one side of the urea, which yielded a substantial improvement in water solubility and oral bioavailability while retaining excellent potency. 24, 25, 32, 33 The adamantyl moiety retained in many of these potent secondgeneration sEH inhibitors provided sensitive characteristic mass spectral fragmentation. However, this moiety is prone to rapid metabolism, often leading to low drug concentrations in the blood and short in vivo half-life.
Replacement of the adamantyl group with a phenyl ring has been explored in our earlier work and has yielded several highly potent inhibitors, warranting further investigation. 25, 33, 34 Thus, in this study, we further investigated urea based sEH inhibitors by optimizing the 1-aryl-3-(1-acylpiperidin-4-yl)urea core structure. On the basis of the reported 2-fold increase in potency of the N-propionylpiperidine over the N-acetylpiperidine in a group of adamantylureas, 25, 32 a series of inhibitors conserving the N-propionylpiperidine moiety was synthesized to probe the SAR of the aryl group. Additional inhibitors conserving 4-trifluoromethoxyphenyl as the aryl group and varying in N-acylpiperidine or N-sulfonylpiperidine substitution were synthesized to examine the effects of polar and basic side chains on potency.
Inhibitors were first screened for potency in vitro against homogeneous recombinant murine sEH and human sEH, and their octanol-water partition coefficients were determined to help direct our search for more "druglike" molecules. Pharmacokinetic screening by oral cassette dosing was then undertaken in mice for 13 piperidines exhibiting *To whom correspondence should be addressed. Phone: 530-752-7519. Fax: 530-752-1537. E-mail: bdhammock@ucdavis.edu.
a Abbreviations: sEH, soluble epoxide hydrolase; EETs, epoxyeicosatrienoic acids; DHETs, dihydroxyeicosatrienoic acids; AUDA, 12-(3-adamantane-1-ylureido)dodecanoic acid; SAR, structure-activity relationship; t 1/2 , half-life; C max , maximum concentration; IC 50 , half maximal inhibitory concentration; AUC, area under the curve; LOQ, limit of quantitation. good in vitro potency and desirable structural characteristics. In addition several bridging compounds were studied to relate this study to previous publications. The in vivo antiinflammatory and analgesic bioactivity of one sEHi were evaluated using carrageenan induced inflammatory pain model.
Chemistry
Scheme 1 outlines the two general synthetic routes used to form the unsymmetrical 1,3-disubstituted urea pharmacophore. Aryl isocyanates were purchased or formed from their corresponding anilines by reaction with triphosgene in the presence of aqueous base. 35 The heptafluoroisopropylanilines required for compounds 38 and 39 were prepared as described. 36 Amine 1 was prepared from 4-aminopiperidine by protection of the primary amine as its benzylimine, 37 reaction with propionyl chloride in the presence of triethylamine, and subsequent deprotection. All isocyanates were reacted with amine 1 to give the desired (1-propionylpiperidin-4-yl)ureas 2-16, 18-21, and 24-40. Saponification of methyl ester 21 with methanolic NaOH afforded benzoic acid 22. Phenol 23 was prepared via 4-benzyloxy isocyanate to avoid formation of a carbamate side product.
Compounds 17 and 31 were prepared by conversion of the corresponding aniline to the intermediate 4-nitrophenyl carbamate, which was then reacted with amine 1 to give the desired urea. Intermediate 41 (Scheme 2) was prepared by the reaction of 4-trifluoromethoxyphenyl isocyanate with 1-BOC-4-aminopiperidine. BOC deprotection gave piperidine 42, which was converted to N-acyl compounds 47-50 and 52 by an EDCI mediated coupling reaction with the respective carboxylic acid. 37 Acetylpiperazine 51 was prepared by debenzylation of 50 and subsequent N-acetylation. Trifluoroacetyl compound 53 was prepared by the reaction of intermediate 42 with ethyl trifluoroacetate. Trihydroxybenzoyl compound 54 was prepared by coupling of 42 with tris-O-benzyl protected gallic acid (44) followed by hydrogenolysis. 38, 39 Intermediate 42 was also converted to N-sulfonyl compounds 55-59 by reaction with the respective sulfonyl chlorides. 
Results and Discussion
Effects of Phenyl Substitution on Potency. In Tables 1-4 a partial structure is shown at the top and the R groups are detailed. Full structures are shown in the Supporting Information along with detailed synthetic methods. Previous studies have shown that the steric bulk of groups adjacent to the urea is positively correlated with inhibitor potency, 26 as was again observed for compounds 2-8 (Table 1 ). This effect is more directly attributed to the hydrophobicity of these groups, as indicated by the positive correlation between potency (-log IC 50 ) and log P values (r = 0.67/0.87, human/murine) for simple side chains in 2-8. Although replacing the cyclohexyl ring (4) with a more compact phenyl ring (7) caused an 11-fold drop in potency against the human enzyme, substitution of the phenyl ring allowed access to electronically and sterically diverse structures (Tables 2 and 3) . Compound 6 provides a bridging structure to recent literature compounds. 27 Inclusion of a pyridine on the left side of the molecule as in compound 9 resulted in a dramatic reduction in potency in the piperidine series, although good potency of such pyridines are reported in the patent literature, 17, 18 and other reports. 22, [27] [28] [29] [30] Inclusion of such polar groups are attractive to improve physical properties, pharmacokinetic properties, and ease of formulation.
Compared to the unsubstituted phenyl compound 7, the inhibition potencies increased dramatically when small nonpolar meta or para (11, 12) substituents were added. Their presence at the ortho position (10) has a clear negative effect on potency. Increasing the size of the hydrophobic para substituent in compounds 12-16 yielded a 3-to 46-fold increase in potency over 7. However, the presence of polar para 50 values were determined with a fluorescent assay using homogeneous recombinant murine and human enzymes (see methods section). b Confidence refers to log P value. See Supporting Information for full explaination.
c The HPLC method used is limited to log P values greater than zero. Table 4 . N-Acyl and N-Sulfonylpiperidine Analogues a nd = Not determined.
because of the high polarity of the nitro functionality, despite having a favorable electron deficient urea. Methyl ester and corresponding carboxylic acid compounds 21 and 22 showed similarly diminished potency. The poor performance of highly polar substituents led us to investigate halophenyl analogues (Table 3) . Halogens can increase polarity as a result of their inherent electronegativity and can also serve to block metabolism at particularly reactive sites and reduce metabolism of the aromatic group by decreasing its electron density. Thus, compounds 24-27 were synthesized to slow metabolic oxidation of the aromatic ring by cytochrome P450 enzymes (CYPs). These compounds also revealed a slight electronic effect on potency, which was less clear in previous studies. 34, 40 The observed increase in potency (-log IC 50 at the catalytic site of the human enzyme (or Asp 333 of the murine enzyme) by inductive withdrawal of the nitrogen lone electron pair, further polarizing the urea N-H bond. Fine optimization of 3,4-and 3,5-disubstituted electron withdrawing groups should yield additional potent compounds. The fluorinated p-isopropyl derivative 38 showed an increase in activity over the corresponding isopropylphenyl derivative 14. As observed previously 40 and for the o-tolyl compound 10, ortho mono-or dihalogenation in compounds 29, 31, and 34 drastically decreased potency. However, this effect may be mitigable by the addition of a large hydrophobic para substituent, such as perfluoroisopropyl in compound 39. It is difficult to discern between hydrophobic and electronic contributions to inhibitor potency in vitro. Experimental log P values and calculated molar volumes (data not shown) are highly predictive of the relative potencies of the carbocyclic, alkylphenyl, and phenyl ether analogues. However, these criteria do not fully account for the high potency observed for halophenyl compounds, highlighting an electronic contribution to inhibitor potency.
Comparison of Piperidine N-Substituents. The 4-trifluoromethoxyphenyl moiety was used as a metabolically stable replacement for the adamantyl ring of our earlier generation of inhibitors 25, 33, 40 and was thus conserved in order to investigate N-substitution of the piperidine moiety. N-Acyl and N-sulfonyl substitution of the 1-(piperidin-4-yl)-3-(4-(trifluoromethoxy)-phenyl)urea core structure (intermediate 42) yielded multiple highly potent inhibitors (Table 4) .
Compounds 47-51 demonstrated the feasibility of introducing a basic nitrogen to allow formulation of the inhibitor as a salt. Analogues 55 and 56 indicate that the sulfonamide group is a good isosteric replacement for the amide, yielding comparably potent inhibitors. These two functional groups may provide valuable pharmacokinetic and pharmacodynamic differences. While bulky substituents on the phenyl moiety improve potency, bulky N-substitution on the piperidine (50, 51, 54, 57-59) did not substantially improve potency over such compounds as 40 or 56. Although bulky N-substitution leads to some increases in potency, previous studies in canines showed that large N-substituents decreased blood levels dramatically following oral administration. 25 Small N-acyl or N-sulfonyl substituents may improve hydrophobic interaction with the enzyme while minimizing the need for conformational change upon entry into the catalytic tunnel. The presence of a small hydrophobic group (52, 53) improved potency approximately 9-fold over compound 40 and reached the LOQ of our in vitro assay. Although highly potent, the hydrolytic instability of the trifluoroacetamide 53 makes it unsuited for in vivo use. Cyclopropanecarboxamide 52, however, is a reasonable modification that improves metabolic stability over propionamide 40 without significantly increasing the molecular weight or log P value. Proper substitution on the phenyl ring is crucial for attaining good potency. A varying degree of polarity, bulk, and basicity is extremely well tolerated by the target enzyme if attached to the piperidine nitrogen, away from the urea pharmacophore.
Pharmacokinetic Screening in Mice. Carbocycle and phenyl substituted ureas significantly improved pharmacokinetics in comparison to the earlier inhibitors AUDA, 34 AEPU (1-[1-acetypiperidin-4-yl]-3-adamantanylurea), 24, 32 and 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl)urea compound 2 32 (Table 5 and Supporting Information). Our results suggest that the adamantane ring is generally less favorable, in terms of ADME, than other groups. The results also demonstrate that molecules can be fine-tuned to optimize ADME and physical properties while retaining high inhibitory potency on the enzyme.
Replacing the adamantane with cycloalkanes in compounds 2-4 resulted in substantially higher blood levels. For example, substitution of the adamantyl ring (2) with a cyclohexyl ring (4) resulted in a 33-fold and 81-fold increase in C max and AUC, respectively, while the cycloheptyl ring (3) increased exposure while retaining potency on the recombinant enzymes ( Figures S4 and S5) . Likewise, the 4-alkylphenyl compounds (12) (13) (14) showed improved PK profiles similar to that of compound 4. Interestingly, homologation of the para-alkyl group altered potency in vitro, with 14 exhibiting the lowest IC 50 against both enzymes, but did not significantly alter PK. The 4-methoxyphenyl (15) surprisingly showed a further increase in C max and AUC by approximately 2-fold and 3-fold, respectively, over compounds 3 and 12-14, suggesting that an ether substituent helps to improve absorption and favorably alters metabolism. Compounds 2-4 and 12-15 were largely cleared in approximately 8 h.
The 4-halophenyl compounds 24, 25, and 27 are more persistent than the former materials and have drastically increased C max and AUC, supporting our hypothesis that metabolism of the 1-aryl-3-(1-propionylpiperidin-4-yl)urea core structure occurs predominantly at the phenyl moiety. To bridge these data to the anticancer drug sorafenib, 42 which is also a potent sEH inhibitor, 43 compound 35 was tested.
The sorafenib-like compound 35 exemplifies excellent stability with two electron withdrawing groups on the phenyl ring. 43 Interestingly, the chlorophenyl compound 25 showed significantly better PK than the other monohalogenated analogues tested. While the lower C max and AUC of 4-iodophenyl compound 27 is likely a consequence of its poor solubility, the large difference between 4-fluorophenyl (24) and 4-chlorophenyl (25) suggests that the improved ADME of 25 is a result of favorable polarity and electronics.
Pain Reduction in Mice. Compound 52 was selected for biological studies as showing both high potency and good pharmacokinetics in mice ( Figures S1-S5 ). Several studies have demonstrated a dramatic reduction of inflammation by sEH inhibitors both alone and when combined with aspirin and nonsteroidal anti-inflammatory drugs. 3 Thus, compound 52 was tested in an inflammation driven pain model (Figure 1 ).
For this study local inflammatory pain was induced by a single, intraplantar injection of carrageenan in rats. The animals' mechanical withdrawal thresholds, expressed as a percent of control, were measured before (baseline) and 3 h after carrageenan administration. At this time vehicle or compounds were administered into the plantar surface of the inflamed paw, indicated by an arrow, in a volume of 10 μL. Mechanical withdrawal thresholds were then monitored (n = 6 per group). Intraplantar carrageenan led to significant pain observed as a dramatic decrease in mechanical withdrawal threshold of animals. This state was sustained over the course of the experiment. The sEHi (10 ng/paw) and morphine (10 000 ng/paw) significantly reversed carrageenan induced pain in a time dependent manner, although the sEHi was more stable than morphine (sEHi vs morphine, ANOVA followed by Dunnett's two-sided t test, p > 0.3) 270 min after treatment even though the dose of the sEH inhibitor was 1000 lower than the morphine dose.
Conclusion
The sEH inhibitors are promising pharmacological leads based on their successful use in multiple models of human disease including prevention and reversal of cardiac hypertrophy 16, 44 and a dramatic reduction of inflammation and pain when used either alone or with nonsterodial anti-inflammatory drugs. 3, 45 As discussed in the Introduction, there are several excellent lead structures under investigation as sEH inhibitors. 17, 18 Disubstituted urea sEH inhibitors with substituted piperidines as the secondary pharmacophore were selected as the focus of this study because they are small, druglike, conformationally restricted structures that are synthetically straightforward. 25, 32 Earlier compounds in this series showed attractive pharmacokinetic properties. 24, 25 Although many criteria are used for the selection of an investigational new drug candidate or a probe for investigating the arachidonic acid cascade in experimental animals, an estimate of exposure indicated by blood levels ( Table 5 , Figures S1-S3) and enzyme inhibition as an indication of potency (Tables 1-4 and S2) are important considerations as are physical properties. When the potential efficacy of compounds is expressed as a function of exposure in murine blood and potency on the recombinant human enzyme, compound 52 represents an improvement of over 10 4 from the bridging compound AUDA reported 10 years ago ( Figure S4 ). 9, 19 It is important to look at a compound's potency in the model species being used, and a similar trend with a 10 5 improvement is seen when murine potency data are used ( Figure S5 ). Evaluation of potency in the model species used is critical. For example, there is a good correlation between data on the recombinant mouse and rat enzymes, while there is not a perfect correlation between IC 50 on human and murine enzymes (r 2 = 0.77; F =0.80; Figure S6 ), and a poor correlation among canine, rodent, and human enzymes particularly for the piperidine containing sEH inhibitors. 25 Figure S3 compares the blood pharmacokinetic profile of compound 52 with that of the closely related bridging compound APAU previously published from this laboratory. 32 The activity of these acylpyperidine compounds is similar on the human and murine recombinant enzymes, but compound 52 is about 30 times more potent on the human than the murine enzyme. 25, 32 The data in Figure S3 indicate a very short half-life and small AUC for APAU. When the AUC/ IC 50 is used as a metric, there is a 5500-fold improvement with compound 52 over the earlier APAU.
Thus, multiple compounds in this series and particularly compounds such as 40 and 52 should be reasonable compounds to use in murine models of disease. Both inhibitors have similar potencies on the rodent and human enzyme and reasonable pharmacokinetics. In particular the data in Figure 1 demonstrate the efficacy of compound 52 in a pain model. More broadly, these data demonstrate rational ways to fine-tune inhibitors in this series as potential therapeutics. It is possible that combinations of these and related structural units will yield highly potent inhibitors and with pharmacokinetics fine-tuned for use in various species.
Experimental Section
General. All reagents and solvents were purchased from commercial suppliers and were used without further purification. All reactions were performed under an inert atmosphere of dry nitrogen. Flash chromatography was performed on silica gel using a dry loading technique, where necessary for poorly soluble products, and elution with the appropriate solvent system. Melting points were determined using an OptiMelt melting point apparatus and are uncorrected. 1 H NMR spectra were collected using a Bruker Avance 500 MHz spectrometer or Varian Mercury 300 MHz spectrometer. Accurate masses were measured using a Micromass LCT ESI-TOF-MS equipped with a Waters 2795 HPLC. The log P and purity analyses were performed using a Hewlett-Packard 1100 HPLC instrument equipped with a diode array detector. A Phenomenex Luna 150 mm Â 4.6 mm, 5 μm, C-18 column was used for all HPLC analyses. For purity analysis, final products were dissolved in MeOH/H 2 O (3:1, v/v) at 10 μg/mL, and 100 μL injections were analyzed in triplicate by HPLC-UV with detection at 210, 230, 254, and 290 nm. HPLC conditions were the same as those for log P determination (see below). Purity was judged as the percent of total peak area for each wavelength. The lowest observed purity is reported. Compounds were also judged to be pure based on thin layer chromatography visualized with short wave UV and stained with basic potassium permanganate. Compounds were g95% pure by HPLC-UV except where specifically noted (see Supporting Information). All compounds were evaluated by LC--MS and NMR specifically to ensure that there was no symmetrical urea impurity present, since these compounds can be very active.
log P Determination. Octanol-water partition coefficients were determined by an HPLC method following OECD Guideline 117. The accepted error for this method is (0.5 log unit of shake flask values (OEDC Guideline 107). Isocratic MeOH/ H 2 O (3:1, v/v), 50 mM ammonium acetate in MeOH/H 2 O (3:1, v/v) adjusted to pH 9.0, and MeOH/H 2 O (3:1, v/v) adjusted to pH 3.0 with H 3 PO 4 were used for neutral, basic, and acidic analytes, respectively, with a flow rate of 0.75 mL/min. The HPLC method was validated using compounds 24 and 54, which were found to have log P values of 1.9 and 2.3, respectively, using the shake flask method (OECD Guideline 107). 25 Many alogrithms for calculation of log P values experience difficulty with urea compounds. For example the r 2 for the correlation for the ClogP values and shake flask values (OECD Guidelines 107 and 122) was <0.3, 25 while the correlation with the HPLC method used herein was ∼0.7 ( Figure S7 ).
Method A: Synthesis of Aryl and Alkyl Isocyanates. The aniline or amine (1 mmol) was added to an ice cold, stirred biphasic mixture of DCM (10 mL) and saturated sodium bicarbonate (10 mL) or 1 N NaOH (3 mL) in brine (7 mL) where noted. Stirring was stopped momentarily, triphosgene (0.37 equiv) in DCM (1 mL) added via syringe to the lower DCM layer, and stirring continued for 10 min. The DCM layer was removed and filtered through a bed of magnesium sulfate. The filtrate was evaporated to afford the corresponding isocyanate, which was used without further purification.
Method B: Synthesis of Ureas via Isocyanate. The isocyanate (1 mmol) was dissolved or suspended in dry THF (3-5 mL) and cooled in an ice bath. The amine (1 mmol) was dissolved in dry THF (1 mL) and slowly added to the reaction. Stirring was continued for 1-24 h at room temperature. The reaction was quenched with dilute HCl (or water where the BOC group was present) and extracted into ethyl acetate. The combined organic phase was dried, evaporated, and purified.
Method C: Synthesis of Ureas via 4-Nitrophenylcarbamate. To an ice cold solution of 4-nitrophenyl chloroformate (1 equiv) in dry THF was added Et 3 N (1.3 equiv), and the appropriate aniline (1 equiv) was dissolved in dry THF. The mixture was allowed to warm to room temperature, stirred for 30 min, and then filtered. The filtrate was evaporated and dissolved in DMF. Amine 1 was added and the mixture warmed to 50°C for 1-3 h. The mixture was cooled to room temperature, diluted with ethyl acetate, and the organic phase washed with 1 N NaOH until the wash was free of yellow p-nitrophenol. The organic phase was dried, evaporated, and purified.
Method D: Synthesis of N-Acylpiperidine Analogues. To a solution of 41 (1 equiv) in DCM were added the corresponding carboxylic acid (1.1 equiv), DMAP (1 equiv), and EDCI (1.1 equiv). The mixture was stirred for 12-24 h at room temperature. Neutral products were worked up by partition with EtOAc and 1 N HCl (basic products by partition with saturated sodium bicarbonate and EtOAc), and the organic phase was dried, evaporated, and purified.
Method E: Synthesis of N-Sulfonylpiperidine Analogues. To a solution of 41 (152 mg, 0.5 mmol) in dry THF (5 mL) were added Et 3 N (1.3 equiv) and the corresponding sulfonyl chloride (1 equiv) in dry THF (1 mL). The mixture was stirred for 12 h, quenched with 1 N HCl, and filtered to collect the resulting precipitate, which was further purified.
Enzyme Purification. Recombinant murine and human sEH were produced in a polyhedron positive baculovirus expression system, and they were purified by affinity chromatography as previously reported. [46] [47] [48] IC 50 Assay Conditions. IC 50 values were determined using a sensitive fluorescent based assay. 49 Cyano(2-methoxynaphthalen-6-yl)methyl trans-(3-phenyloxyran-2-yl)methylcarbonate (CMNPC) was used as the fluorescent substrate. Human sEH (1 nM) or murine sEH (1 nM) was incubated with the inhibitor for 5 min in pH 7.0 Bis-Tris/HCl buffer (25 mM) containing 0.1 mg/mL BSA at 30°C prior to substrate introduction ([S] = 5 μM). Activity was determined by monitoring the appearance of 6-methoxy-2-naphthaldehyde over 10 min by fluorescence detection with an excitation wavelength of 330 nm and an emission wavelength of 465 nm. Reported IC 50 values are the average of three replicates with at least two data points above and at least two below the IC 50 . The fluorescent assay as performed here has a standard error between 10% and 20%, suggesting that differences of 2-fold or greater are significant. 49 Pharmacokinetic (PK) Studies. Male CFW mice (7 week old, 24-30 g) were purchased from Charles River Laboratories. All the experiments were performed according to protocols approved by the Animal Use and Care Committee of University of California, Davis. Inhibitors (1 mg each) were dissolved in 1 mL of oleic ester-rich triglyceride containing 20% polyethylene glycol (average molecular weight: 400) to give a clear solution for oral administration. Since many of these compounds are high melting and relatively water insoluble, it is important that they are in true solution to study their pharmacokinetics. The 20% PEG 400 in oleic ester rich triglyceride gave true solutions for all compounds reported. To avoid ill defined levels of linoleate esters (18:2) in the vehicle, we used the synthetic triglyceride of oleic esters (18:1) or triolein for vehicle. Cassette 1 contained compounds 2, 24, 25, and 27, cassette 2 compounds 12, 13, and 14, cassette 3 compounds 3, 4, and AUDA, cassette 4 compounds 2, 15, and 35, and cassette 5 compounds 40 and 52. Each cassette was orally administered to three or four mice at a dose of 5 mg/kg in 120-150 μL of vehicle depending on animal weight. Blood (10 μL) was collected from the tail vein using a pipet tip rinsed with 7.5% EDTA (K3) at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 24 h after oral dosing with the inhibitor. The blood samples were prepared according to the methods detailed in our previous study. 24 Blood samples were analyzed using an Agilent 1200 series HPLC instrument equipped with a 4.6 mm Â 150 mm Inertsil ODS-4 3 μm column (GL Science Inc., Japan) held at 40°C and coupled with an Applied Biosystems 4000 QTRAP hybrid, triple-quadrupole mass spectrometer. The instrument was equipped with a linear ion trap and a Turbo V ion source and was operated in positive ion MRM mode (see Table S1 ). The solvent system consisted of water/acetic acid (999/1 v/v, solvent A) and acetonitrile/ acetic acid (999/1 v/v, solvent B). The gradient was begun at 30% solvent B and was linearly increased to 100% solvent B in 5 min. This was maintained for 3 min, then returned to 30% solvent B in 2 min. The flow rate was 0.4 mL/min. The injection volume was 10 μL, and the samples were kept at 4°C in the autosampler. Optimized conditions for mass spectrometry are in Table S1 .
For clarity standard deviation is not included in Figure S1 . There is less than 5% variation in compound levels in replicate blood samples from the same mice. Thus, the standard deviation shown in Figure S2A -F represents variation among mice treated with the same compound. The PK parameters of individual mice were calculated by fitting the time dependent curve of blood inhibitor concentration ( Figure S2 ) to a noncompartmental analysis with the WinNonlin software (Pharsight, Mountain View, CA). Parameters determined include the time of maximum concentration (T max ), maximum concentration (C max ), half-life (t 1/2 ), and area under the concentration-time curve to terminal time (AUC t ). In separate studies to determine dose linearity of selected compounds, pharmacokinetic parameters determined by cassette dosing were found to be predictive of results from dosing individual compounds. 24, 50 Figure S3 compares the pharmacokinetics of compound 52 with that of the bridging compound APAU. 24, 25, 32 Graphs of exposure as a function of potency are shown in Figures S4 and S5 .
Inflammatory Pain Model. This study was approved by UC Davis Animal Care and Use Committee. Male Sprague-Dawley rats weighing 250-300 g were obtained from Charles River Inc. and maintained in UC Davis animal housing facilities with ad libitum water and food on a 12 h/12 h light-dark cycle. Behavioral nociceptive testing was conducted by assessing mechanical withdrawal threshold using an electronic von Frey anesthesiometer apparatus (IITC, Woodland Hills, CA). 45 The controller was set to "maximum holding" mode so that the highest applied force (in gram) upon withdrawal of the paw was displayed. Three measurements were taken at 1-2 min interstimulus intervals. Data were normalized to percentage values using the formula (mechanical withdrawal threshold (g)) Â 100)/(mechanical withdrawal threshold (g)) before carrageenan. Compound 52 was tested using the intraplantar carrageenan elicited inflammatory pain model. Following baseline measurements, carrageenan (50 μL, 1% solution of carrageenan) was administered into the plantar area of one hind paw. Three hours following this, postcarrageenan responses were determined. Immediately after, the vehicle (10 μL of PEG400), the sEH inhibitor, or morphine sulfate (10 μg in 10 μL saline) was administered into the same paw by intraplantar injection in a volume of 10 μL. Responses following compound administration were monitored over the course of 2.5 h. -3-(1-acylpiperidin-4-yl) . Relative blood pharmacokinetic profiles of key compounds. The compounds were dosed orally to CFW mice at 5 mg per kg. In this figure compounds 2 and AUDA have blood levels that are indistinguishable from baseline. The standard deviation of repeated injections of the same extract averages 3% and of repeated extracts average 5%, and they are not shown in this figure for clarity. The standard deviation shown in the subsequent figures thus represents variation among replicate mice. The pharmacokinetic parameters determined from cassette dosing are very similar to those for select compounds that were dosed individually. Blood levels of all compounds are shown with an expanded scale in S2. AUDA in this figure and APAU in Figure S5 are bridging compounds to compare potency [1] [2] [3] [4] [5] [6] [7] [8] and pharmacokinetic data 9-11 to previous studies. Table 5 . S2A. Blood pharmacokinetic profiles of halogenated phenyl sEH inhibitors compared to compound 2. Figure S2B . Blood pharmacokinetic profiles of two substituted phenyl sEH inhibitors compared to the standard sEH inhibitor 2. These data and data in figure 1 and S2E indicate that the adamantane is a metabolic liability in this class of compounds based on blood concentrations. The adamantane moiety has been used extensively in previous studies due to ease of monitoring adamantane containing compounds in the blood by LC-MS and due to the high potency and selectivity associated with it as a substituent. The 4-chloro-3-trifluoromethylphenyl derivative 35 has a phenyl substituent identical to the anti-cancer urea Sorafenib (Nexavar). 12 The very long half-life of 35 is consistent with an increase in logP and suggests very slow metabolism or enterohepatic circulation. Alkoxy derivatives such as 15 are commonly metabolized rapidly by O-dealkylation, but this sEH inhibitor is surprisingly stable in vivo and is more stable than alkyl groups in the para-position . Figure S2C . Blood pharmacokinetic profiles of alkyl phenyl sEH inhibitors. All three sEH inhibitors appear to be cleared quickly from the blood, presumably largely by ω and ω-1 hydroxylation. The potency of the compounds increases with the lipophilicity and size of the alkyl group with the perfluoroisopropylphenyl derivative 38 the most active. Figure S2D . Blood pharmacokinetic profiles of two cycloalkyl ureas compared to the commercial sEH inhibitor AUDA. Note that blood levels are higher for these cycloalkyl compounds than the corresponding adamantane derivative (2) in Figure S2E below. Figure S2E . Blood pharmacokinetic profiles of the standard sEH inhibitor for this study 2 compared to the commercially available sEH inhibitor AUDA. Compound 2 illustrates the use of the piperidine as a 'secondary pharmacophore' which increases water solubility and decreases the logP of the sEH inhibitors as illustrated earlier for the piperidines by Jones and associates. 4 In other series a polar group placed 7-8 Å from the carbonyl of the central pharmacophore has provided improved selectivity and water solubility without loss of potency. A variety of polar substituents have been used in other studies as the secondary pharmacophore. These data show a significant improvement in pharmacokinetics with a similar IC 50 on the murine and human recombinant enzymes. AUDA data presented here and in Table  5 are very similar to previously published data but were generated specifically for this study to aid in comparison of different publications.
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Figure S2F. Blood pharmacokinetic profiles of two highly potent and stable sEH inhibitors. Compound 40 (also known at 1770 or TPPU) is approximately 10 times less potent, has a slightly higher Cmax, slightly shorter half life and smaller AUC than the cyclopropyl compound 52. Figure S3 . Blood pharmacokinetic profiles of compounds 52 and the bridging compound APAU 4 after single oral dosing to mice at a dose of 1 mg/kg. Please note that this figure is on a log scale. Compound 52 showed AUC t /IC 50 (x10 4 min) for the human and murine enzymes of 935 (note that AUC t is from the mouse in both cases) while the chemically related APAU (1-(1-acetypiperidin-4-yl)-3-adamantanylurea) resulted in ratios of only 0.17 and 0.13 respectively. For more detailed pharmacokinetic data on APAU see Liu et al. 9 for murine and Tsai et al. 11 for canine data. Figure S5 . In vivo exposure (estimated as area under the curve from Figure S2 , Table 5 ) as a function of potency (-log IC 50 ) on the homogenous, recombinant murine sEH (IC 50 from Table S2) IC 50 Human sEH (nM) There is a high correlation between the IC 50 determined on the affinity purified human and murine soluble epoxide hydrolase using CMNPC as substrate. Two statistics were used to evaluate the data including a linear regression or r 2 and a Spearman rank correlation or rho. Although the correlation is high there are clear outliers indicating that the fine structure of the catalytic site of the human and murine sEHs have some clear differences. This correlation is particularly poor with compounds similar to those reported here for canine vs human and rodent enzymes. a 12-(3-cyclohexan-1-yl-ureido)-dodecanoic acid (CUDA) was used as an internal standard to track instrument stability. b 1-(1-acetypiperidin-4-yl)-3-adamantanylurea (APAU) was used as an internal standard added after thawing samples but before extraction to track the extraction efficiency of structurally similar target analytes. 50 value. The fluorescent substrate Cyano(2-methoxynaphthalen-6-yl)methyl trans-(3-phenyl-oxyran-2-yl) methyl carbonate (CMNPC). A caution is that this assay can over estimate the potency of sEH inhibitors in the piperidine and some other classes of compounds relative to assays based on other surrogate substrates or epoxyeicosanoids.
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Detailed synthetic methods 1-(4-Aminopiperidin-1-yl)propan-1-one (1). 4-Aminopiperidine (4.01g, 40mmol) and benzaldehyde (4.251g, 40mmol) were dissolved in toluene (70mL) and refluxed on a Dean-Stark trap until water ceased to evolve. The solvent was evaporated and the residue was reconstituted in dry THF (75mL).
Triethylamine (4.04g, 40mmol) was added and the reaction was cooled in an ice bath. With vigorous stirring, propionyl chloride (3.70g, 40mmol) was added and the reaction continued for 1.5 hours at rt.
The reaction was filtered, and the filtrate was evaporated and treated with 1N HCl (50mL) for 1 hour. 
1-(1-Adamantyl)-3-(1-propionylpiperidin-4-yl)urea (2).
1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea (4).
1-(trans-2-Phenylcyclopropyl)-3-(1-propionylpiperidin-4-yl)urea (6). trans-2-Phenylcyclopropyl
isocyanate
1-Phenyl-3-(1-propionylpiperidin-4-yl)urea (7).
Phenyl isocyanate was reacted with 1 by Method B. 
1-(Naphthalen-2-yl)-3-(1-propionylpiperidin-4-yl)urea (8
1-(1-Propionylpiperidin-4-yl)-3-(pyridin-3-yl)urea (9)
.
1-(1-Propionylpiperidin-4-yl)-3-p-tolylurea (12). p-Tolyl isocyanate was prepared from p-toluidine
1-(4-Ethylphenyl)-3-(1-propionylpiperidin-4-yl)urea (13). 4-Ethylphenyl isocyanate was prepared
), 7.07 (dd, J = 7.9, 7.9 Hz, 1H), 6.92 (brd, J = 7.2 Hz, 4H), 6.14 (d, J = 7.5 Hz, 1H), 4.18 (d,
1-(4-Morpholinophenyl)-3-(1-propionylpiperidin-4-yl)urea (19). 4-Morpholinophenyl isocyanate
was prepared from 4-morpholinoaniline by Method A using 1M NaOH in brine as the base and was was added and the reaction continued for 2 hours before cooling to RT The reaction was quenched with 1N HCl (20mL), the organic solvent removed and the remaining suspension filtered to give compound 294.1587. 
1-(2-Fluorophenyl)-3-(1-propionylpiperidin-4-yl)urea (29).
1-(3,4-Dichlorophenyl)-3-(1-propionylpiperidin-4-yl)urea (32
